Search Results
Nov 11, 2025, 09:00 ET IBN Technologies Managed Cloud Services and Multi-Cloud Consulting Drive Scalable, Secure Digital Transformation
DevSecOps Maturity Assessment to identify gaps and opportunities Secure CI/CD integration with SAST, DAST, and IaC scanning tools Policy‑as‑Code enforcement, automated compliance gates, and OWASP prevention
More news about: IBN Technologies
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
Stem-like CD8+ T Cell Amplification: ILKN421H selectively expands PD1- stem-like CD8⁺ T cells, a subset capable of self-renewal and durable antitumor immunity.
More news about: iLeukon Therapeutics
Nov 10, 2025, 13:12 ET Lanzamiento del reproductor portátil de alta fidelidad HiBy RS8 II de gama ultraalta
resolución. La simulación de tonalidad Sankofa AI ofrece a usuarios disfrutar de firmas de sonido inspiradas en fuentes de audio clásicas como MD, CD, casetes y reproductores de cintas de bobina abierta, con actualizaciones gratuitas para una experiencia de alta fidelidad personalizada.
More news about: HiBy
Nov 10, 2025, 11:43 ET Lanzamiento del reproductor HiFi portátil ultra insignia HiBy RS8 II
simulación de tonalidad Sankofa AI permite disfrutar de firmas sonoras modeladas a partir de fuentes de audio clásicas como reproductores de MD, CD, casete y cinta de carrete abierto, con actualizaciones gratuitas para una experiencia HiFi personalizada.
More news about: HiBy
Nov 10, 2025, 11:33 ET HiBy RS8 II Ultra-Flaggschiff unter den tragbaren HiFi-Playern veröffentlicht
hochauflösende Audiowiedergabe. Die Sankofa-AI-Klangsimulation ermöglicht Nutzern, Klangsignaturen zu genießen, die klassischen Audioquellen wie MD-, CD-, Kassetten- und Tonbandgeräten nachempfunden sind, und bietet kostenlose Updates für ein individuelles HiFi-Erlebnis. Das Design
More news about: HiBy
Nov 10, 2025, 11:13 ET Medicom Now Fully Contracted with 17 of 18 VA Regions, Announces New VISN 10 and 17 Agreements
partners. This supports community care coordination under the Mission Act by providing a digital alternative to manual processes like the transport of CD-ROMs. The platform also provides VA staff with a search capability to locate and retrieve prior medical images from community providers.
More news about: Medicom Technologies, Inc.
Nov 10, 2025, 11:04 ET Sortie du RS8 II, le lecteur hi-fi portable phare de HiBy
tonalité Sankofa AI permet aux utilisateurs de profiter de signatures sonores inspirées de sources audio classiques telles que les minidisques, les CD, les cassettes et les bandes magnétiques, avec des mises à jour gratuites pour personnaliser l'expérience hi-fi. En matière de
More news about: HiBy
Nov 10, 2025, 10:38 ET Verismo Therapeutics Presents Promising Preclinical Data at SITC 2025 for SynKIR™-110 in Solid Tumors
exhibited reduced cell exhaustion, lower off-target toxicity, and robust tumor regression in vitro and in vivo compared to conventional (41BB-CD3ζ) CAR T The oral presentation was selected as one of the Top 150 abstracts out of more than 1,300 submissions
More news about: Verismo Therapeutics
Nov 10, 2025, 08:46 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
More news about: NOVO NORDISK INC.
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
More news about: NOVO NORDISK INC.
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Nov 10, 2025, 07:00 ET CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
dose of drug (p<0.05). Three-day dosing of Auxora reduced Th-17 cells in the lung by 59% versus placebo and IL-6-producing CD4 cells by 69% (each p<0.05). Auxora significantly improved kidney function at 72 hours, with greater GFR recovery (p˂0.01)
More news about: CalciMedica, Inc.
Nov 10, 2025, 05:00 ET Vipshop to Announce Third Quarter 2025 Financial Results on November 20, 2025
https://register-conf.media-server.com/register/BIa4c765227cd84d4fb940f017c5724abc Once pre-registration has been completed, each participant will receive dial-in numbers
More news about: Vipshop Holdings Limited
Nov 07, 2025, 17:00 ET Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet
2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749) und hat zum ersten Mal gezeigt, dass aus CD34+ hämatopoetischen Stammzellen (HSC) gewonnene dendritische Zellen, die so verändert wurden, dass sie CD40L, CD93 und CXCL13 übermäßig produzieren, eine starke Anti-Tumor-Wirkung in humanisierten Mausmodellen
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 16:49 ET Lunai Bioworks、前臨床のヒト化モデルにおいて、原発および転移性膵臓がんの完全退縮を達成──オールロジェニックがん免疫療法における画期的なブレークスルーを示す
て重要なものとなっている。 今回の新たな論文は、Lunai が以前に発表した研究（Vaccines 2025年7月12日; 13(7):749; doi:10.3390/vaccines13070749）を基盤とするものである。同研究では、ヒト化マウスの膵がんモデルにおいて、CD40L、CD93、CXCL13 を過剰発現させた CD34+ 造血幹細胞（HSC）由来樹状細胞（DC）が強力な抗腫瘍活性を示すことが初めて示された。初期研究では研究用グレードのレンチウイルスベクターを使用していたが、今回の最新報告では、将来的な臨床応用を見据え、設計および製造面を改善しつつ同等の有効性を維持した、最適化された臨床対応型コンストラクトについて記載している。
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 14:46 ET Nirmata Launches AI Platform Engineer to Automate Cloud-Native Infrastructure Governance and Management
freeing engineers to focus on higher-value innovation. The AI Platform Engineering Assistant supports all common Kubernetes, Infrastructure-as-Code, and CI/CD systems, with native support for multi-cluster Kubernetes management and seamless integration with existing developer workflows.
More news about: Nirmata, Inc
Nov 07, 2025, 12:49 ET Tech hiring intent unexpectedly increases in October, according to CompTIA analysis of job posting data
CI/CD
More news about: CompTIA
Nov 07, 2025, 09:55 ET HiBy RS8 II Ultra-Flagship Portable HiFi Player Released
high-resolution audio reproduction. Sankofa AI tonality simulation allows users to enjoy sound signatures modeled after classic audio sources such as MD, CD, cassette, and reel-to-reel tape players, with free updates for a personalized HiFi experience. In terms of design, the RS8 II
More news about: HiBy
Nov 07, 2025, 09:13 ET HiBy RS8 II Ultra-Flagship Portable HiFi Player Released
high-resolution audio reproduction. Sankofa AI tonality simulation allows users to enjoy sound signatures modeled after classic audio sources such as MD, CD, cassette, and reel-to-reel tape players, with free updates for a personalized HiFi experience. In terms of design, the RS8 II
More news about: HiBy
Nov 07, 2025, 09:00 ET HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers
HCB101's progress reflects its distinct engineering compared to earlier CD47-targeting approaches. First-generation CD47 antibodies, such as magrolimab and lemzoparlimab, demonstrated clinical activity but faced significant safety or efficacy challenges,
More news about: HanchorBio Inc.
Nov 07, 2025, 09:00 ET Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
Most common adverse events were mild flu-like symptoms. Post-vaccination CD127 upregulation on circulating T-cells and Granzyme B upregulation in circulating CD8+ cells were observed, suggesting enhanced T cell activity.
More news about: Diakonos Oncology
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
Shinobi publishes its first public data in a poster presentation at the 2025 SITC Conference, titled, "Systemic and regionally infused iPSC-Derived CD8 αβ T Cells Mediate Tumor Killing via TCR- and Innate Receptor-Dependent Mechanisms Enhanced by Cytokine Armoring." The poster will be presented
More news about: Shinobi Therapeutics
Nov 07, 2025, 07:26 ET TOUCHMARK BANCSHARES, INC. REPORTS THIRD QUARTER RESULTS
opportunities." Krimmel continued, "We strategically reduced our non-core deposit balance during the quarter and shifted retail CD customers to money market accounts to improve the balance sheet mix. We added a new Senior Credit Officer and successfully disposed of a piece of OREO
More news about: Touchmark Bancshares, Inc.
Nov 07, 2025, 02:00 ET Lunai Bioworks réussit à éliminer complètement les tumeurs pancréatiques primaires et secondaires dans des modèles humanisés précliniques, marquant une avancée significative pour l'immunothérapie allogénique contre le cancer
doi:10.3390/vaccines13070749), qui a démontré pour la première fois une puissante activité antitumorale des CD34+ dérivées de cellules souches hématopoïétiques (CSH) et modifiées pour surexprimer les CD40L, CD93 et CXCL13 dans des modèles murins humanisés de cancer du pancréas. Alors que l'étude initiale utilisait
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 02:00 ET Lunai Bioworks logra la regresión completa de tumores pancreáticos primarios y metastásicos
primera vez la potente actividad antitumoral de las células dendríticas (DC) derivadas de células madre hematopoyéticas (HSC) CD34+, modificadas genéticamente para sobreexpresar CD40L, CD93 y CXCL13 en modelos de ratón humanizados de cáncer de páncreas. Si bien el estudio inicial utilizó un vector lentiviral
More news about: Lunai Bioworks Inc.